Consider clinically relevant pharmacokinetic drug interactions when co-prescribing drugs in attention-deficit/hyperactivity disorder

AbstractPolypharmacy is common in the treatment of attention-deficit hyperactivity disorder (ADHD). However, the use of multiple drugs increases the risk of pharmacokinetic drug –drug interactions (DDIs) and subsequent adverse safety outcomes. Clinically relevant pharmacokinetic DDIs can be prevented by adjusting the dose of the ADHD drug or, if possible, by using an alternative drug that would not have a pharmacokinetic effect on the ADHD drug.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research